Research and development of a new therapy for lung carcinoma focused on miR-143.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10271
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Tokyo Medical University
• Principal Investigator: Matsubayashi Jun 東京医科大学, 医学部, 准教授 (00338790)
• Co-Investigator(Kenkyū-buntansha): 大平 達夫 東京医科大学, 医学部, 教授 (40317847) ; 池田 徳彦 東京医科大学, 医学部, 主任教授 (70246205) ; 高梨 正勝 東京医科大学, 医学部, 講師 (80312007) ; 岩館 寛大 山陽小野田市立山口東京理科大学, 工学部, 准教授 (70279107)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺腺癌 / miRNA / KRAS

Outline of Final Research Achievements

In our study, we focused on lung adenocarcinoma with the KRAS mutation to identify a new therapy for KRAS-mutated lung adenocarcinoma using miRNA to target KRAS. We examined the miRNAs correlated to the 3’-untranslated region of KRAS from the miRNA database. Among these miRNAs, we focused on four in particular, including miR-143. We analyzed the expressions of KRAS and these miRNAs in a human adenocarcinoma cell line by transfection of each of the four miRNAs mimics. Although the expression of KRAS in the lung adenocarcinoma cell line was not knocked down by transfection of any of these mimics, the expression was knocked down by transfection of a mixture of the four mimics.

Free Research Field

病理学